A5014822929- Blood groups and transfusion
- Blood transfusion and management
- Complement system in diseases
- Renal Diseases and Glomerulopathies
- COVID-19 Clinical Research Studies
- Hematopoietic Stem Cell Transplantation
- Hematological disorders and diagnostics
- Protein Degradation and Inhibitors
- Blood donation and transfusion practices
- Acute Myeloid Leukemia Research
- Palliative Care and End-of-Life Issues
- Quality and Safety in Healthcare
- SARS-CoV-2 and COVID-19 Research
- Cancer Genomics and Diagnostics
Cancer Research UK Manchester Institute
2024
University of Manchester
2024
Bristol Royal Infirmary
2020
University Hospitals Bristol NHS Foundation Trust
2019
At Bristol
2018
Acute thrombotic thrombocytopenic purpura (TTP) is a life-threatening emergency and plasma exchange (PEX) the initial treatment shown to reduce acute mortality.To compare current practice in United Kingdom (UK) against standards set out 2012 British Society of Haematology guideline, better understand issues affecting prompt initiation PEX.The trainee research network HaemSTAR conducted retrospective nationwide review adults presenting UK hospitals with first episode TTP.Data on 148 patients...
The epigenetic factors KAT6A (MOZ/MYST3) and KMT2A (MLL/MLL1) interact in normal hematopoiesis to regulate progenitors' self-renewal. Both proteins are recurrently translocated AML, leading impairment of critical differentiation pathways these malignant cells. We evaluated the potential different therapeutic targeting strategies alter growth rearranged AMLs.
Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare, life-threatening disease, characterised by episodes of microangiopathic haemolytic anaemia (MAHA), thrombocytopenia and small vessel thrombosis. We describe case cTTP first diagnosed at age 70 years in female presenting with an acute ischaemic stroke thrombocytopenia, whom A Disintegrin And Metalloproteinase Thrombospondin type 1 Motif, member 13 (ADAMTS13) levels were <10%, suggestive thrombocytopaenic (TTP). The patient...
A 76-year-old woman on warfarin for atrial fibrillation presented routine pacing check 6 weeks after implantation of a dual-chamber device. She felt weak and generally unwell. The lead was not sensing or at high outputs. chest X-ray …
Current National Institute for Health and Care Excellence (NICE) guidance recommends restrictive thresholds red cell transfusion, dependent upon patient factors such as haemodynamic status.1 NICE also that individuals should be provided with information regarding the risks benefits of blood transfusion those patients give informed consent prior to transfusion. Informed is a recurrent theme in Infected Blood Inquiry.2 We audited (RCTx) practices according guidelines examined documentation...